Bloomberg Johnson & Johnson made its biggest deal ever in a bold bet that it can get more growth out of medicines for a rare type of high blood pressure. The $30 billion purchase of Swiss drugmaker Actelion Ltd., which J&J is funding with cash it holds outside the US, will fulfill its goal of gaining a new drug ...
Read More »